Detailed narrative
Modern Oral Growth and Market Share Expansion
Turning Point Brands reported significant growth in its Modern Oral segment, with gross sales up 149% and net sales up 128% year-over-year. This performance was driven by expanding retail distribution for both Free and ALP brands, as well as strong direct-to-consumer platforms. Modern Oral now constitutes 48% of total revenue, demonstrating successful market share gains and consumer resonance in the evolving nicotine category.
Strategic Investments in Infrastructure and Sales Force
The company is making substantial investments to support its Modern Oral growth, including increasing its sales force by approximately 50% this year to service new accounts and ensure product availability and merchandising. These investments are critical for executing successfully at retail and are expected to lead to leverage over a larger revenue base as the retail footprint and sales expand.
US Manufacturing and Margin Improvement
Subject to regulatory approval, Turning Point Brands is on track to launch US manufacturing by the end of 2026. This initiative is expected to significantly reduce the cost of goods sold (COGS) over time⏳, with a target of achieving gross margins of approximately 70% once fully scaled. This move is a key component of the long-term strategy to build profitable nicotine pouch businesses.
Heritage Business Performance and Stabilization
The Stoker's tobacco segment saw net sales increase 55% year-over-year, with heritage Stoker's brands experiencing a slight 1% decrease, driven by MST share growth offsetting loose leaf declines. The Zigzag segment's performance was in line with expectations, with net sales down 4% sequentially. The company is sharpening its new product pipeline and leveraging its sales force to stabilize these heritage businesses, which continue to generate strong cash flow for Modern Oral investments.
Regulatory Environment and PMTA Progress
The company's PMP (Premarket Tobacco Product) application is progressing well and remains in process with the FDA. Management acknowledges the resource-intensive and uncertain timing of📎 the regulatory process but expresses confidence in its expertise to navigate dynamic regulatory environments. An additional $3 million to $5 million is expected to be spent in 2026 to support these applications.
International Expansion Strategy
Turning Point Brands has begun a phased expansion of its ALP brand into select European markets. The international strategy involves partnering with local entities to manage regulatory and sales burdens, rather than establishing a full sales force, reflecting a disciplined approach to new market entry.